Type 2 diabetes patients: MRI is worth the price

Diabetes Mellitus: Long-term Prognostic Value of Whole-Body MR Imaging for the Occurrence of Cardiac and Cerebrovascular Events

1. Fabian Bamberg, MD, MPH, 
2. Klaus G. Parhofer, MD, 
3. Elena Lochner, BS,
4. Roy P. Marcus, BS, 
5. Daniel Theisen, MD, 
6. Hannes M. Findeisen, MD,
7. Udo Hoffmann, MD, MPH, 
8. Stefan O. Schönberg, MD, 
9. Christopher L. Schlett, MD, MPH, 
10. Maximilian F. Reiser, MD and 
11. Sabine Weckbach, MD

1. From the Department of Clinical Radiology (F.B., E.L., R.P.M., D.T., M.F.R., S.W.) and Department of Internal Medicine II (K.G.P.), Ludwig Maximilians University, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany; Department of Cardiology, University Hospital RWTH Aachen, Aachen, Germany (F.B., H.M.F.); Cardiac MR PET CT Program, Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (U.H., C.L.S.); Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Mannheim, Germany (S.O.S.); and Department of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany (S.W., C.L.S.).

1. Address correspondence to
   F.B. (e-mail: fbamberg@med.lmu.de).

1. Author contributions: Guarantors of integrity of entire study, F.B., S.W.; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; manuscript final version approval, all authors; literature research, F.B., E.L., D.T., U.H., S.O.S., M.F.R., S.W.; clinical studies, F.B., K.G.P., E.L., R.P.M., D.T., H.M.F., S.O.S., M.F.R., S.W.; statistical analysis, F.B., D.T., U.H., C.L.S.; and manuscript editing, F.B., K.G.P., E.L., R.P.M., D.T., U.H., S.O.S., C.L.S., M.F.R., S.W.
   

Abstract

Purpose: To study the predictive value of whole-body magnetic resonance (MR) imaging for the occurrence of cardiac and cerebrovascular events in a cohort of patients with diabetes mellitus (DM).

Materials and Methods: This HIPAA-compliant study was approved by the institutional review board. Informed consent was obtained from all patients before enrollment into the study. The authors followed up 65 patients with DM (types 1 and 2) who underwent a comprehensive, contrast-enhanced whole-body MR imaging protocol, including brain, cardiac, and vascular sequences at baseline. Follow-up was performed by phone interview. The primary endpoint was a major adverse cardiac and cerebrovascular event (MACCE), which was defined as composite cardiac-cerebrovascular death, myocardial infarction, cerebrovascular event, or revascularization. MR images were assessed for the presence of systemic atherosclerotic vessel changes, white matter lesions, and myocardial changes. Kaplan-Meier survival and Cox regression analyses were performed to determine associations.

Results: Follow-up was completed in 61 patients (94%; median age, 67.5 years; 30 women [49%]; median follow-up, 70 months); 14 of the 61 patients (23%) experienced MACCE. Although normal whole-body MR imaging excluded MACCE during the follow-up period (0%; 95% confidence interval [CI]: 0%, 17%), any detectable ischemic and/or atherosclerotic changes at whole-body MR imaging (prevalence, 66%) conferred a cumulative event rate of 20% at 3 years and 35% at 6 years. Whole-body MR imaging summary estimate of disease was strongly predictive for MACCE (one increment of vessel score and each territory with atherosclerotic changes: hazard ratio, 13.2 [95% CI: 4.5, 40.1] and 3.9 [95% CI: 2.2, 7.5], respectively), also beyond clinical characteristics as well as individual cardiac or cerebrovascular MR findings.

Conclusion: These initial data indicate that disease burden as assessed with whole-body MR imaging confers strong prognostic information in patients with DM.

© RSNA, 2013

Supplemental material:http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.13130371/-/DC1